Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Clinical trial NCT02485535 · COMPLETED

Trial details

NCT number: NCT02485535
Sponsor: University of Chicago
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia de Novo Myelodysplastic Syndrome Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome

Start date: 2015-09-04
Primary completion: 2018-02-28
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.